Eli Lilly’s weight-loss drug no longer in shortage, FDA says The announcement is a blow to the compounding pharmacies that have made cheaper, off-brand versions of the medication.

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply.

The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the United States after more than a year of being in shortage, according to the Food and Drug Administration’s ...

The shortage of Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday. Indianapolis-based Eli Lilly’s supply of ...

News weighs on stocks of companies offering alternatives and some smaller ones developing their own drugs The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs ...